Comparative Pharmacology
Head-to-head clinical analysis: NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE versus PSEUDO 12.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE versus PSEUDO 12.
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE vs PSEUDO-12
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naphazoline is an alpha-adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness and edema. Pheniramine is a histamine H1-receptor antagonist that blocks the effects of histamine, reducing itching and allergic symptoms.
Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.
1-2 drops or sprays in each nostril every 4-6 hours as needed, not to exceed 5-7 days
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
None Documented
None Documented
Naphazoline: Terminal elimination half-life approximately 2-3 hours; clinical effects may persist longer due to local vasoconstriction. Pheniramine: Terminal elimination half-life approximately 14-16 hours; appropriate for twice-daily dosing.
Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
Naphazoline: Renal excretion of unchanged drug and metabolites accounts for >80% of elimination. Pheniramine: Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with <5% biliary/fecal elimination.
Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Category C
Category C
Ophthalmic Antihistamine/Decongestant
Decongestant